Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)
Historic Net Income towards Common Stockholders for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.8 million.
- Benitec Biopharma's Net Income towards Common Stockholders fell 8654.66% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$37.9 million, marking a year-over-year decrease of 6949.93%. This contributed to the annual value of -$37.9 million for FY2025, which is 6949.93% down from last year.
- According to the latest figures from Q2 2025, Benitec Biopharma's Net Income towards Common Stockholders is -$8.8 million, which was down 8654.66% from -$14.5 million recorded in Q1 2025.
- In the past 5 years, Benitec Biopharma's Net Income towards Common Stockholders registered a high of -$3.5 million during Q1 2022, and its lowest value of -$14.5 million during Q1 2025.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$4.8 million (2021), whereas its average is -$5.8 million.
- In the last 5 years, Benitec Biopharma's Net Income towards Common Stockholders skyrocketed by 2303.36% in 2024 and then tumbled by 23888.76% in 2025.
- Over the past 5 years, Benitec Biopharma's Net Income towards Common Stockholders (Quarter) stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then decreased by 20.98% to -$6.8 million in 2023, then plummeted by 40.51% to -$9.6 million in 2024, then increased by 7.82% to -$8.8 million in 2025.
- Its Net Income towards Common Stockholders was -$8.8 million in Q2 2025, compared to -$14.5 million in Q1 2025 and -$9.6 million in Q4 2024.